Virchow Biotech
Vamsi Krishna Ravula is a Senior Research Associate at Virchow Biotech since September 2020, bringing extensive experience in the biotechnology sector. Prior to this role, Vamsi worked as an R&D Executive at Unique Biotech from January 2018 to September 2020. Earlier in career, Vamsi contributed to Bioserve Biotechnologies India Pvt Ltd as part of a project focused on the screening of lead toxicity-induced genetic effects in children in mid-2013, and briefly engaged in RFLP studies at Indegenises India Pvt Ltd in June 2012. Vamsi holds a Master’s degree in Resource Recovery with a specialization in Industrial Biotechnology from the University of Borås (2015-2017) and a Bachelor's degree in Biotechnology from KL University (2010-2014).
This person is not in any teams
This person is not in any offices
Virchow Biotech
Virchow Biotech (P) Ltd is an ISO 13485:2012 and WHO-GMP certified leading global player in Biopharma sector having around 20 years of operational experience and is situated at Hyderabad, India. We also have offices located in USA. Throughout the years, the company has been successful in Research and development, clinical trials, large-scale production and Commercialization of Plasma Products, Recombinants, Biologicals and Bio-Pharmaceuticals. With 1160 employees on the board, VBPL has an expansive infrastructure, which comprises of WHO cGMP and USFDA certified state-of-art clean-room manufacturing facilities and excellent fill-finish lines for PFS, vials, cartridges and lyophilized drug products. VBPL focuses on the manufacturing of a wide range of biologicals and bio-generics by genetic engineering, classical fermentation or extraction technologies. Apart from this, we also offer Contract Research and Manufacturing services, co-development of products for various markets and customers around the world. Virchow Biotech is the part of Virchow Group incorporated in 1981. Other group companies are leading manufacturers of Sulphamethoxazole, Ranitidine, Cephalosporins and various other APIs. VBPL's achievements include being the first company in the world to commercialize biogenerics of PDGF, Teriparatide, Pegylated Interferon and Rasburicase. VBPL has a wide product portfolio across Woundcare, Gynaecology, Urology, Oncology, Vaccines and Probiotics etc. Our mission is to provide high quality Biopharma products at an affordable price. Serving economically challenged patients across the globe through Biotechnology by extending our product base across various therapeutic segments.